Drug Profile
Elobixibat - Albireo Pharma/EA Pharma
Alternative Names: A-3309; AJG-533; GooficeLatest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer Albireo Pharma; EA Pharma; Eisai Co Ltd; Mochida Pharmaceutical; Synmosa Biopharma; Yokohama City University
- Class 2 ring heterocyclic compounds; Amides; Antihyperlipidaemics; Carboxylic acids; Hepatoprotectants; Irritable bowel syndrome therapies; Laxatives; Small molecules; Sulfides; Sulfones; Thiazepines
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Constipation
- Discontinued Dyslipidaemias; Irritable bowel syndrome; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis